Genaera's board of directors has decided to make John 'Jack' L. Armstrong, Jr. its CEO and president. Armstrong was appointed interim CEO several weeks ago.
SkyePharma Chairman Ian Gowrie-Smith resigned in the face of a shareholder revolt.
Immtech International has named Eric L. "Rick" Sorkin as CEO.
MicroIslet has appointed James R. Gavin III, M.D., Ph.D., as its interim president and CEO.
Celsion founder Augustine Cheung has acquired a subsidiary of the company and will leave to operate it.
Exagen Diagnostics has named Robert Mignatti as president and COO.
Nektar Therapeutics has named Louis Drapeau as senior vice president, finance and CFO.
Alimera Sciences has named Richard S. Eiswirth as the company's CFO.
Axcan Pharma has appointed Steve Gannon as CFO and senior vice president, replacing Jean Vezina who was named vice president of finance.
Targeted Genetics named David J. Poston as vice president, finance, CRO and treasurer.
Cardium Therapeutics has appointed Randall W. Moreadith, M.D., Ph.D., as executive vice president and chief medical officer.
PerkinElmer has named Dr. Aaron Geist as vice president, business development.
ViroPharma has made the following supplements to management: Vincent Milano, ViroPharma's vice president and CFO, will also act as the company's COO; Clayton Fletcher has been promoted to vice president, business development; Thomas Lembck has been promoted to vice president, information technology; Stephen Villano, M.D., has been promoted to vice president, clinical research and development; and Debra Gayda, Ph.D., has been appointed as vice president, regulatory affairs.
ZIOPHARM Oncology has appointed Robert Morgan, MS, JD, as vice president of regulatory affairs and quality, and contract counsel.
BioXell has promoted Meenu Chhabra to chief business officer.
Xenomics has appointed Dr. Mark O'Hara as director of product development.
454 Life Sciences named Katherine Webster as vice president for measurement services center sales.
WuXi PharmaTech announced the appointment of Dr. Angela Wong as vice president of service biology.
Pfizer has named Amal Naj vice president, investor development and strategy. He succeeds Jim Gardner, who will retire in April after 29 years of service to Pfizer.
Blaine Pharmaceuticals has made several new hires: Michael Saig was named to its team as director of national accounts and Bethany Flick was named marketing associate.
Intranasal Therapeutics has formed a Scientific Advisory Board chaired by Jordan L. Cohen, Dean of the College of Pharmacy at the University of Iowa. Others on the board are: Paul Ashton, Ph.D; Jacqueline A. French, M.D.; Sveinbjorn Gizurarson, Ph.D.; Sam R. Sharar, M.D.; and Daniel P. Wermeling, Pharm.D.
Advantage Software has added Nicholas Allen, associate director, business development for PharmaNet, to its board of advisors.
OncoMethylome Sciences has elected Philip S. Schein, M.D., F.R.C.P to its board of directors.
Targanta Therapeutics has elected William W. Crouse to its board of directors.